Загрузка...
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection. TAF has been shown to be a potent inhibitor of HBV replication at a low dose, with high intracellular concentration and more than 90% lower systemic TFV...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683768/ https://ncbi.nlm.nih.gov/pubmed/29158666 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S126742 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|